

## Article

# Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles

Maria Camilla Operti,<sup>1</sup> Yusuf Dölen,<sup>1,2</sup> Jibbe Keulen,<sup>1</sup> Eric A.W. van Dinther,<sup>1,2</sup> Carl G. Figdor,<sup>1,2</sup> and Oya Tagit<sup>1,2,\*</sup>

<sup>1</sup>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, and

<sup>2</sup>Oncode Institute, The Netherlands

\* Correspondence: oya.tagit@radboudumc.nl

**Abstract:** Polymeric particles made up of biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA) are promising tools for several biomedical applications including drug delivery. Particular emphasis is placed on the size and surface functionality of these systems as they are regarded as the main protagonists in dictating the particle behavior *in vitro* and *in vivo*. Current methods of manufacturing polymeric drug carriers offer a wide range of achievable particle sizes, however, they are unlikely to accurately control the size while maintaining the same production method and particle uniformity, as well as final production yield. Microfluidics technology has emerged as an efficient tool to manufacture particles in a highly controllable manner. Here, we report on tuning the size of PLGA particles at diameters ranging from sub-micron to microns using a single microfluidics device, and demonstrate how particle size influences the release characteristics, cellular uptake and *in vivo* clearance of these particles. Highly controlled production of PLGA particles with ~100 nm, ~200 nm and >1000 nm diameter is achieved through modification of flow and formulation parameters. Efficiency of particle uptake by dendritic cells and myeloid-derived suppressor cells isolated from mice is strongly correlated with particle size and is most efficient for ~100 nm particles. Particles systemically administered to mice mainly accumulate in liver and ~100 nm particles are cleared slower. Our study shows the direct relation between the particle size varied through microfluidics and the pharmacokinetics behavior of particles, which provides a further step towards the establishment of a customizable production process to generate tailor-made nanomedicines.

**Keywords:** PLGA; drug delivery systems; microfluidics; nanoparticles; microparticles

## 1. Introduction

As evidenced by the dramatic increase in the number of studies and clinical applications over time, polymeric particles play a crucial role in drug delivery, providing improved stability, targeted delivery and sustained release of the loaded therapeutic agents without causing off-target toxicities *in vivo* [1-5]. Drug delivery particles based on poly(lactic-co-glycolic acid) (PLGA) are among the most commonly studied vehicles due to excellent biocompatibility, tuneable degradation characteristics and long clinical history of PLGA [6-8]. The remarkable physicochemical properties and high versatility of PLGA have proven to address several challenges in drug delivery. PLGA can be processed into almost any size and shape [7] and can encapsulate molecules of virtually any size such as small drugs [9-13], proteins [14-18], nucleic acids [19-23], and vaccines [24-29]. The colloidal features such as size and surface functionality have a direct influence on the cellular uptake, biodistribution, and thus therapeutic efficacy of the particles, dictating the *in vivo* fate of therapeutic cargo [30,31]. These colloidal features are particularly important in cancer immunotherapy as the efficacy of any given therapeutic agent is highly dependent on its ability to reach either the tumor

microenvironment (TME) or the lymph nodes. The incomplete endothelial lining due to rapid angiogenesis at the tumor site results in the formation of large and irregular pores (0.1-3  $\mu\text{m}$ ) [32], through which nanoparticles can escape from the circulatory stream and accumulate at the TME via a so-called enhanced permeability and retention (EPR) effect [32]. Toy et al. demonstrated that, within the size range of 60-130 nm, smaller particles exhibited greater lateral drift towards the blood vessel walls, which is a prerequisite for interaction with the tumor vascular bed and essential for escape into the TME [33]. Furthermore, both blood clearance and uptake by the mononuclear phagocyte system (MPS) at the liver and spleen depend on the size and composition of PLGA carrier systems. The slit size in the inter-endothelial cells of the spleen is about 200 nm, which facilitates the leakage and circulation of smaller particles for longer time periods [34] or enables their entry to lymphatic system through direct drainage to the lymph nodes [35]. On the other hand, larger particles, which are not eligible for intravenous administration due to their excessive size, are more likely to be taken up by immune cells at the injection site in case of e.g. subcutaneous or intramuscular pathways [36].

Surface functionality also influences drug pharmacokinetics *in vivo*. The use of polyethylene glycol (PEG) has been shown to significantly increase circulation time in several studies [36-38]. When attached to nanoparticles' surface (a process so-called PEGylation), the hydrophilicity of PEG chains recruits specific proteins from plasma, that cloak and limit the interactions of particles with MPS cells, hence prolonging the blood circulation ('stealth effect') [39,40]. The decrease in the aggregation, opsonization, and phagocytosis of particles entails the extension of their circulation time. Morikawa et al. reported additional benefits of PEGylation such as reduced particle size and improved encapsulation efficiency for curcumin-loaded nanoparticles [41].

In addition to particle size and surface functionality that have a large influence on the therapeutic efficacy *in vivo*, particle uniformity in terms of size and encapsulated cargo is also an important aspect particularly for the clinical translation of polymeric drug delivery formulations [42,43]. The uniformity of particles depends largely on the utilized manufacturing approach. The conventional production techniques based on emulsion solvent diffusion, emulsion solvent evaporation and nanoprecipitation are suitable for the production of sub-micron and micron-size PLGA particles [7,8], however, these methods lack the precision and full control over the particle size and uniformity particularly for larger scale processes [8]. In recent years, microfluidics technology has emerged as an effective tool to produce particles in a highly controllable manner [44,45]. Major advantages of microfluidics-based particle manufacturing include the requirement of low sample volumes, high surface area, and reduced system footprint [46]. This technology allows for rapid fluid mixing at the nanoliter scale and production of PLGA particles with highly specific sizes as well as surface functionalities only by altering specific parameters such as concentration of the starting materials or fluid flow rates through micron size channels [41,47-52]. Additionally, traditional small-scale laboratory synthesis techniques suffer from batch-to-batch variations while microfluidics technology provides a precise size control, a high degree of particle uniformity and reproducibility. Furthermore, formulations can be scaled up by increasing the quantities of fluids pumped through the system or by parallelizing multiple microfluidic mixers [53].

In this study, we report on the use of microfluidics technology as a platform for the production of PEGylated PLGA particles. We explored the feasibility to generate different sizes of particles with low polydispersity index (PDI) by varying process and formulation parameters such as total flow rate and flow rate ratio of organic and aqueous phases as well as surfactant and polymer concentration. We tuned the particle size at sub-micron (~100 nm and ~200 nm) and micrometer (>1000 nm) length scales, which represent biologically-relevant cut-off values that influence the particle biodistribution and clearance *in vivo*. A fluorescent dye was used as a model drug to assess encapsulation efficiency, release profile, and uptake by mouse-derived immune cells. Biodistribution and clearance of systemically administered, fluorescently labeled particles were also studied on a mouse model through *in vivo* imaging.

## Experimental

### Materials:


PLGA (Resomer RG 502H), with a 50:50 ratio of lactic acid:glycolic acid and Mw 7 000–17 000 Da was obtained from Evonik Nutrition & Care GmbH. PEG-PLGA copolymer (PEG  $M_n$  5000, PLGA  $M_n$  7000), polyvinyl alcohol (PVA, 9000–10 000 Mw, 80 %, hydrolyzed) and cholesteryl BODIPY<sup>TM</sup> FL C<sub>12</sub> were obtained from Thermo Fisher. Near-infrared emitting fluorescent dye VivoTag-S 750 was purchased from Perkin Elmer and acetonitrile (ACN, 99.95 %) was from VWR. Ultrapure Milli-Q<sup>®</sup> water (18.2 M $\Omega$ .cm) was used where necessary (Merck). RPMI-1640 medium, Anti-Anti (AA), and  $\beta$ -mercaptoethanol were obtained from Gibco. GM-CSF was obtained from Peprotech. X-Vivo medium and ultraglutamine were from Lonza. Fetal Bovine Serum (FBS) was purchased from Hyclone (GE Healthcare).

### Equipment:

The microfluidics system was set up by connecting syringe pumps (Harvard PHD-2000 infusion 70–200) to a Y-junction mixer with staggered herringbone ridges (NanoAssemblr<sup>TM</sup>, Precision Nanosystems Inc.) through 0.8 mm PFTE tubing (ID 0.8 mm, OD 1.58 mm, Sigma-Aldrich). A detailed characterization of the mixing geometry was reported in [44]. Two 20 mL NORM-JECT Luer Lock syringes were connected to 0.8 mm diameter needles (Braun Sterican 0.8 x 120 mm), which were inserted in the fittings connected to the inlets of the mixing cartridge. A PFTE tubing connected to the chip outlet was used for sample collection.

### Preparation of PLGA particles:

Prior to particle production, the pipes and the mixing chip were primed first with the solvents (ACN for the organic phase inlet and MilliQ for the aqueous phase inlet) and then with the appropriate phases for 1 minute at organic:aqueous flow rates of 2:2. After the priming step, pumps were operated at the desired flow rates. The product obtained within the first 2 minutes was discarded. The collected particles were left stirring overnight (350 rpm) at room temperature for organic solvent evaporation. A schematic representation of the process is shown in Scheme I.



**Scheme I:** Schematic illustration of the particle generation process via nanoprecipitation method using a Y-junction mixing cartridge.

The particle size was tuned via varying the flow rates of organic and aqueous phases as well as PLGA and PVA concentrations. Upon determination of the optimized parameters for each target size,

PEGylated PLGA particles encapsulating fluorescent dyes emitting either at visible or near-infrared regions were prepared by the following methods:

*>1000 nm particles:* the organic phase (5 mL ACN) contained 233.1 mg PLGA, 99.9 mg PEG-PLGA and 50  $\mu$ L of 1 mg/mL fluorescent dye in ethanol. A 3 % PVA solution was used as the aqueous phase. Particles were produced at 6:2 organic:aqueous flow rates in triplicates.

*~200 nm particles:* the organic phase (5 mL ACN) contained 116.6 mg PLGA, 50 mg PEG-PLGA and 50  $\mu$ L of 1 mg/mL fluorescent dye in ethanol. A 1 % PVA solution was used as the aqueous phase. Particles were produced at 2:6 organic:aqueous flow rates in triplicates.

*~100 nm particles:* the organic phase (8 mL ACN) contained 93.5 mg PLGA, 40 mg PEG-PLGA and 80  $\mu$ L of 1 mg/mL fluorescent dye in ethanol. A 1 % PVA solution was used as the aqueous phase. Particles were produced at 4:6 organic:aqueous flow rates in triplicates.

After evaporation of the organic solvent, particles were washed three times with MilliQ water by centrifugation at 15 000 rpm for 35 minutes (for >1000 nm and ~200 nm particles) and by spin filtration using a 100 000 kDa MW cut-off centrifugal filter device (Millipore, Merck) for ~100 nm particles. Particles were then lyophilized.

### **Colloidal characterization of PLGA particles:**

1.25 mg of lyophilized particles were dispersed in 1 mL of MilliQ water to determine the size distribution and polydispersity index (PDI) with dynamic light scattering using a Nanotract Flex (Microtrac). Zeta potential measurements were obtained with a Zetasizer Nano ZS (Malvern Instruments). Prior to measurements, particles were suspended in a 50 mM NaCl solution. The average of three measurements were used to report the size, PDI and Zeta potential for each sample.

Atomic force microscopy (AFM) images of particles were obtained with a Catalyst BioScope (Bruker) coupled to a confocal microscope (TCS SP5II, Leica). 50  $\mu$ L of 10 mg/mL particle suspension was dried on clean glass substrates and particles were imaged in peak-force tapping mode using a silicon nitride cantilever with nominal spring constant of 40 N/m (Bruker). AFM images were analyzed using NanoScope analysis software (Bruker).

### **Determination of encapsulation efficiency:**

Dye loading was quantified by construction of a calibration curve using a BODIPY- $C_{12}$  standard. A series of dye concentrations (in 0-0.25 mg/mL range) were prepared in a solvent composed of equal parts of ACN and MilliQ and fluorescence intensities were measured for each standard. The fit function applied to the linear portion of the curve was used for the calculation of the dye content of particles. The encapsulation efficiency was determined by comparing the total amount of dye in the lyophilized particles to the initial amount of dye supplied for the collected volume.

### ***In situ* release profile:**

PLGA particles containing BODIPY- $C_{12}$  were suspended in PBS in 5 mg/mL concentrations and were dialyzed at 37°C for 14 days using dialysis tubes with a 1 000 Da molecular weight cut-off membrane (GE Healthcare). At different incubation times, the dialysis medium was collected for fluorescence measurements using an LS 55 Perkin Elmer fluorescence spectrometer. Samples were excited at 488 nm and emission was recorded between 500 nm and 700 nm. After each measurement the dialysis medium was refreshed. Samples were studied in triplicates.

### ***In vitro* cellular uptake experiments:**

#### ***Generation of BMDCs***

Dendritic cells were generated from mouse bone marrow cells by culturing them in full RPMI medium containing 5 mL 200mM L-Glutamine (Gibco), 5 mL 100x Antibiotics & Antimicrobials (Gibco), 10% Fetal bovine serum (Gibco), and 500  $\mu$ L  $\beta$ -mercapto ethanol (Sigma-Aldrich).  $5.0 \times 10^6$  cells in 13 mL of full medium were cultured in the presence of 20 ng/mL GM-CSF for 7 days. At day 3, 4 mL of

complete medium containing 37.9 ng/mL GM-CSF was added. At day 6, 1 mL complete medium containing 158 ng/mL GM-CSF was added. Cells were used for uptake experiments at day 7.

#### *Isolation of mMDSCs and pmnMDSCs*

Gr-1<sup>dim</sup>Ly-6G<sup>-</sup> monocytic and Gr-1<sup>high</sup>Ly-6G<sup>+</sup> polymorphonuclear myeloid derived suppressor cells (mMDSCs and pmnMDSCs, respectively) were isolated from the spleen of tumor-bearing mice using an isolation kit (Miltenyi Biotec) according to manufacturer's instructions. Briefly, spleen was isolated under sterile conditions and was meshed through a 100  $\mu$ m cell strainer with a syringe plunger. The cell suspension was spun at 400xg for 5 minutes and resuspended in 3 mL of 1x ammonium chloride solution for the lysis of erythrocytes. After 5 minutes of incubation at room temperature, cells were washed with 10 mL of PBS. The cells were incubated with an Anti-Ly-6G-Biotin antibody and Anti-Biotin MicroBeads and were subsequently applied to a MACS Column, which retained the pmnMDSCs. The flow-through containing mMDSCs were eluted as the positively selected cell fraction and were further purified by applying them to a second MACS Column.

#### *In vitro cellular uptake*

$1.0 \times 10^5$  cells in 500  $\mu$ L complete medium were transferred to 5 mL propylene round bottom tubes (Falcon). 10  $\mu$ g of particles containing BODIPY-C<sub>12</sub> water were added to the round bottom tubes and were incubated for time periods of 1, 2, 4, 6, 24 and 48 hours. After incubation, particle uptake was determined by flow cytometry analysis on a FACSVerse (BD biosciences).

#### ***In vivo biodistribution and clearance studies:***


All animal experiments were performed according to guidelines of animal care of the Nijmegen Animal Experiments Committee in accordance with the ethical standards described in the declaration of Helsinki. Wild-type BALB/cAnNCrI aged 8-12 weeks mice were obtained from Charles River, Germany and maintained under specific pathogen-free conditions at the Central Animal Laboratory (Nijmegen, the Netherlands). Drinking water and food were provided ad libitum. Mice were warmed either in a heating chamber or under a heating lamp and 1 mg PLGA nanoparticles (~200 nm and ~100 nm) containing VivoTag-S 750 were injected in 200  $\mu$ L of PBS solution through a lateral tail vein using a 1mL syringe with a 29G needle. 0.5, 3, 24, and 48 hours after injections mice were shaved and imaged in an IVIS Lumina II (Perkin Elmer) system. Mice were euthanized, and organs were dissected and imaged separately at 24 and 48 hours. Imaging settings were, Exposure time: 3sec, Binning: Medium, F/Stop:2, Fluorescent Excitation filter:745nm, Fluorescent Emission filter: 810-885nm. A fluorescent background acquisition was performed for each time point. Living Image software (Caliper Lifesciences) was used for data analysis. Background values were subtracted from measurement values. Same sized ROI's were applied on liver and bladder for full body image analysis; also same sized ROI's were applied on the isolated liver and spleen. Total flux (photon/second) per each ROI was calculated.

#### **Results and discussion:**

##### **Preparation of particles**

A commercially available NanoAssemblr™ cartridge [8] connected to syringe pumps was used for the production of PLGA particles through nanoprecipitation. In this method, water-miscible organic solvents are used to dissolve the polymer and the solvent diffusion coefficient plays a critical role in the obtained particle size [54]. In our study, acetonitrile (ACN) was used as the organic phase and particles were formed upon rapid mixing of organic and aqueous phases in micron-size channels. Due to rapid diffusion of ACN to the aqueous phase, PLGA precipitates and is subsequently stabilized by PVA present in the aqueous phase. Process parameters such as (total) flow rates of organic and aqueous phases as well as formulation parameters such as PLGA and PVA concentration were varied to tune the size of PLGA particles from sub-micron to micron-scales.

The first process parameter tested was the flow rate of the organic phase composed of a 33.3 mg/mL PLGA solution in ACN. The organic phase flow rate was varied between 2 mL/min and 6 mL/min while the aqueous flow rate was kept constant at 2 mL/min for a 1 % PVA solution (Figure 1A). A gradual increase in the particle size from ~400 nm to ~900 nm was observed with an increase of the organic phase flow rate. This is most likely caused by precipitation of higher amounts of PLGA at a given mixing time when relatively higher organic phase flow rates were used. Similarly, increasing the flow rate of the aqueous phase for a given set of formulation parameters and organic phase flow rate resulted in the formation of smaller particles (Figure 1B). Doubling the aqueous flow rate to 4 mL/min resulted in particles almost half the size of those produced at 2 mL/min. However, increasing the aqueous flow rate up to 6 mL/min did not result in a notable change in particle size.



**Figure 1.** Influence of process and formulation parameters on the particle size. The variation of particle size at different flow rates for 33.3 mg/mL PLGA as organic phase and 1% PVA as aqueous phase (A-C). D) The influence of PLGA concentration on the particle size (organic:aqueous flow rate of 4:4 mL/min, 3% PVA as aqueous phase). (Bars: intensity-averaged particle size; Green dots: PDI).

Another process parameter affecting particle size was the total flow rate of the organic and aqueous phases. With the equal flow rate of organic and aqueous phases, the increase of the total flow rates from 4 mL/min (2:2) to 8 mL/min (4:4) led to a decrease of the particle size (Figure 1C). Increasing the total flow rate further to 12 mL/min (6:6), however, did not cause any notable difference in the particle size other than a slight improvement in the PDI. The total flow rate determines both the mixing time of the two phases in the cartridge and the collection rate of the particles at the outlet channel. Faster mixing by increasing the total flow rates has also been reported in other studies to result in the formation of smaller particles [41,47].

Overall, particles in the sub-micron size range were obtained by varying only the flow parameters. Furthermore, we varied the PLGA and PVA concentrations in order to increase the particle size to micron scale. A representative data set in Figure 1D shows that particle size almost tripled when the PLGA concentration was doubled. In these batches, the PVA concentration was increased as well and organic:aqueous flow rates were kept equal (4:4 mL/min). The larger particle

size obtained with higher PLGA concentration can be explained by the higher viscosity of the organic phase, which resulted in a slower diffusion of ACN to the aqueous phase and an increased mixing time [55].

For all tested conditions, a good batch-to-batch reproducibility and a small PDI ( $\leq 0.2$ ) was observed. After several trials, the optimal conditions and parameters were determined to obtain particles of sizes  $>1000$  nm,  $\sim 200$  nm and  $\sim 100$  nm. These parameters were then used to prepare particles with a surface functionalized with polyethylene glycol (PEG) and encapsulating a fluorescent dye (Table 1).

**Table 1.** Optimized formulation and process parameters to obtain PLGA particles with indicated size.


Parameters	$>1000$ nm	$\sim 200$ nm	$\sim 100$ nm
PLGA (mg/mL)	66.6	33.3	16.7
PLGA:PEG-PLGA ratio	70:30	70:30	70:30
PVA (w/v %)	3%	1%	1%
Flow rates (mL/min) (QO:QA)	6:2	2:6	4:6
Fluorescent dye (v/v %)	1%	1%	1%

For fluorescent labelling, two different fluorescent dyes with visible (BODIPY<sup>TM</sup> FL C<sub>12</sub>, green, 510 nm) and near-infrared (VivoTag-S 750, red, 750 nm) emission wavelengths were used. BODIPYs are low-polarity dyes with stable fluorescence emission properties [56] and are commonly used in fluorescence detection and photodynamic therapy applications [57]. VivoTag-S 750 is a near-infrared emitting (NIR) fluorochrome extensively used for *in vivo* imaging applications [58,59]. PLGA particles labelled with the green fluorescent dye were used for *in situ* release and *in vitro* uptake experiments, whereas those labelled with the red dye were used for *in vivo* imaging studies.

### Colloidal characterization

A detailed colloidal and functional characterization of PEGylated PLGA particles encapsulating BODIPY-C<sub>12</sub> is shown in Figure 2. Both atomic force microscopy (AFM) images (Figure 2A-C) and dynamic light scattering (DLS) measurements (Figure 2D) revealed the formation of monodisperse particles (PDI  $\leq 0.2$ ) within the desired size range (i.e.;  $> 1000$  nm,  $\sim 200$  nm,  $\sim 100$  nm) also upon PEGylation and fluorescent dye encapsulation. The micron-sized particles showed an average size of 1690 nm ( $\pm 60$  nm), while the sub-micron particles were 250 nm ( $\pm 48$  nm) and 106 nm ( $\pm 5$  nm) in diameter. For ease of reporting, we will continue referring to them as ' $>1000$  nm,  $\sim 200$  nm,  $\sim 100$  nm particles. Slightly negative  $\zeta$  potential values that spanned a range between  $-5$  mV and  $-15$  mV were observed for all particle types (Figure 2E). While the variation of  $\zeta$  potential was negligible among sub-micron particles (i.e.  $\sim 200$  nm,  $\sim 100$  nm), the micron-size particles displayed the most negative value. PLGA nanoparticles stabilized with PVA have also been reported to bear a slightly negative  $\zeta$  potential ( $-5$  mV) [60] due to the presence of residual PVA on the particle surface, which affects the number of carboxylic acid end groups [61]. The hydrophobic acetate moieties in partially hydrolyzed PVA can lead to its entrapment within PLGA matrix on the particle surface, thereby mask the surface charges to almost neutral  $\zeta$  potential values [62]. Therefore, the more negative  $\zeta$  potential obtained for micron-size particles can be related to differences in the PVA content and the flow rate of aqueous phase for micron-size particles compared to sub-micron particles, as well as the higher PLGA content.

Apparently, these variations in formulation and process parameters influence not only the particle size but also the particles' surface properties, which collectively determine the pharmacokinetic properties, cellular uptake, and particle biodistribution [63].



**Figure 2.** Atomic force microscopy height images of >1000 nm (A), ~200 nm (B) and ~100 nm (C) PLGA particles. The scale bars display the Z-range and the scan sizes are shown on x-axis. Size distribution (D) and  $\zeta$  potential values (E) of PLGA particles measured using dynamic light scattering. F) Release profile of BODIPY-C<sub>12</sub> from >1000 nm, ~200 nm, ~100 nm particles. Data obtained for >1000 nm, ~200 nm and ~100 nm particles are represented in orange, blue and red, respectively.

Encapsulation efficiency of BODIPY-C<sub>12</sub> was determined using fluorescence spectroscopy by comparing the initial amount of dye supplied during particle production and the total amount of dye detected in the entire yield. The efficiency of dye encapsulation was significantly higher for smaller particles with the highest efficiency of 44 % for ~100 nm particles, which decreased gradually to 21 % and 13 % for ~200 nm and >1000 nm particles, respectively. It should be noted that each particle type was produced using different formulation and process parameters, which equally play a role in determining the encapsulation efficiency [64]. An efficient encapsulation requires the rapid precipitation of polymer with the fluorescent dye to restrict the dye within the polymer matrix and prevent its diffusion to the aqueous phase. The micron-size particles with the lowest encapsulation efficiency were prepared using the highest polymer concentration and the highest organic:aqueous phase flow rate ratios. The high viscosity of organic phase as well as the relatively low fraction of aqueous phase probably resulted in a slower polymer precipitation, and therefore a lower encapsulation efficiency for micron-size particles.

The functional characterization of particles was achieved by monitoring the dye release. For this study, particles dispersed in PBS were dialyzed at 37°C for a period of 14 days. At certain time points, fluorescence intensities of the dialysis media were measured using fluorescence spectroscopy. The dialysis medium was replaced with a fresh medium after each measurement. Each formulation type showed a distinct release profile that was strongly correlated with the particle size. After an initial burst, the release was steady for all particles (Figure 2F). The magnitude of burst release was higher for ~100 nm particles (approx. 30 %), which was found as ~15 %, and ~10 % for ~200 nm and >1000 nm particles, respectively.


In addition to the highest burst release, the overall release rate was also faster for ~100 nm particles such that they released the majority of their content (~80 %) already by day 4. On the other hand, the released content of ~200 nm and >1000 nm particles barely reached at 50 % and 20 %, respectively, by the end of the entire release period (2 weeks). Indeed, several different release patterns such as mono-, bi- and tri-phasic release are reported for PLGA particles, which are mainly regulated by the physicochemical properties of the cargo, PLGA type (molecular weight, lactide/glycolide ratio, etc) and particle morphology (size, porosity, etc) [65]. Since the same cargo

and polymer type were used for the preparation of particles, the main reason for different release rates observed was the particle size. Larger surface area/volume ratio of smaller particles facilitated the faster diffusion of dye molecules located on or close to the surface. Such inverse relation between the release rate and particle size is in good agreement with the general trends reported in other studies [66–68].

### *In vitro* uptake experiments

Particle size and surface functionality are among the key parameters that influence their interactions with cells [69]. In this work, we used mouse-derived cells, namely bone marrow-derived dendritic cells (BMDCs), CD103<sup>+</sup> dendritic cells (CD103<sup>+</sup>) and myeloid-derived suppressor cells (MDSCs) of monocytic (mMDSCs) and polymorphonuclear (pmnMDSCs) sub-types to study the uptake of fluorescently labelled, PEGylated PLGA particles of varying sizes (Figure 3).

Particles incubated with BMDCs for different time periods were analyzed using flow cytometry (Figure 3A). In our previous study we reported that, once taken up by the cells, the integrity of PLGA particles is compromised before 72 h of incubation [70]. Hence, in the present work, we monitored particle uptake up to 48 h in order to avoid possible variations in the mean fluorescence intensities (MFI) due to particle degradation at later time points. For ease of comparison, MFI data were normalized to 1 for the values obtained at 48 h of incubation time. A clear correlation between the particle size and the trend in particle uptake was observed. For sub-micron particles (~100 nm and ~200 nm) a stable MFI was observed within the first 6 h, which increased at later time points (Figure 3A, red and blue curves). On the other hand, micron-size particles (>1000 nm) showed a time-dependent uptake behaviour. For these particles, the intracellular MFI increased gradually within the first 6 h, reaching a plateau until the end of the incubation period (Figure 3A, orange curve).



**Figure 3.** Intracellular mean fluorescence intensity (MFI) values obtained for >1000 nm (orange), ~200 nm (blue) and ~100 nm (red) PLGA particles incubated with BMDCs for different time periods (A),

and correlation between the particle size and intracellular MFI after 2h of incubation with CD103<sup>+</sup> dendritic cells (B), monocytic MDSCs (C) and polymorphonuclear MDSCs (D) isolated from mouse. Data were obtained using flow cytometry.


Overall, the uptake of sub-micron particles was more efficient compared to micron-size particles. The MFI obtained at 1 h of incubation already corresponded to ~75 % and ~50 % of the total MFI for 100 nm particles (Figure 3A, red) and 200 nm particles (Figure 3A, blue), respectively. It should be noted that each type of PLGA particles had different dye loading ratios. In this uptake study, equal amounts of PLGA particles with different total fluorescence intensities were used. Although normalization of MFI enabled a fair comparison of the particle uptake trend for different sizes, we further investigated the particle uptake on other types of mouse-derived immune cells using particles with equal fluorescence intensities instead of equal particle mass (Figure 3B-D). A clear correlation between the particle size and intracellular MFI was observed for the cells that were either generated *in vitro* (Figure 3B) or were isolated from the spleen of tumor-bearing mice (Figure 3C-D). After 2 h incubation period, the uptake of ~100 nm particles was ~1.5 fold higher than the >1000 nm particles for CD103<sup>+</sup> dendritic cells (Figure 3B) and mMDSCs (Figure 3C), and the difference was even higher (almost 3 fold) for pmnMDSCs (Figure 3D). Similar studies also reported the lower uptake efficiencies of micron-size particles compared to sub-micron particles by dendritic cells [71], which could be due to different uptake mechanisms associated with different particle sizes. The uptake of small particles (<100 nm) has been reported to be clathrin- and/or caveolin-mediated [72], whereas micropinocytosis and phagocytosis are main mechanisms via which sub-micron particles (~200 nm) and micron-sized particles (>1000 nm) are taken up [73]. In addition to particle size, surface charge is an important parameter that influences the efficiency of particle uptake by cells. Prior to their internalization, particles need to attach on the cell surfaces that are decorated with negatively charged proteoglycans [63]. Consequently, the uptake of positively-charged particles can be more efficient due to electrostatic interactions between the particles and cell surface. In our work, all particles had negative  $\zeta$  potential values, which was highest for >1000 nm particles. Therefore, the poorer uptake efficiency observed for micron-size particles can be due to less-favorable surface charge in addition to larger particle size.

All the cell types used in our work are important regulators of immune response. BMDCs and CD103<sup>+</sup> are antigen presenting cells that can prime T cells to induce antigen-specific immune responses [74]. On the other hand, MDSCs play an important role in immune suppression in cancer as well as in tumor angiogenesis, drug resistance, and promotion of tumor metastases [75], representing an attractive potential therapeutic target in e.g. cancer immunotherapy. Among the studied PLGA formulations, ~100 nm particles with almost neutral surface charge would be the most efficient vehicle to deliver e.g. antigens to DCs and immunomodulatory drugs to MDSCs for cancer immunotherapy.

### ***In vivo* clearance of particles**

Rapid clearance of particles from the bloodstream through the mononuclear phagocyte system (MPS) and reticuloendothelial system (RES) represents a major limitation to achieve preferential accumulation of particles in the target organs [76]. Tuning the size and surface properties of particles has proven useful in preventing their rapid removal from the bloodstream [77,78]. In order to evaluate particle clearance *in vivo*, we administered PLGA particles labelled with a near-infrared (NIR)-emitting dye (VivoTag-S 750) intravenously (i.v.) to mice. The acceptable particle size range for the i.v. injections have been reported as 10 nm - 1000 nm to prevent possible accumulation of larger particles in the lung capillaries [61,79,80]. Therefore, we used only sub-micron size particles for *in vivo* studies. The colloidal properties of ~100 nm and ~200 nm particles encapsulating the NIR-emitting dye were similar to those labelled with the green fluorescent dye (Supp. Fig.1). Whole-body and *ex-vivo* organ imaging was performed at different time points up to 48 h after i.v. administration of sub-micron PLGA particles (Figure 4).

Whole-body imaging revealed the presence of both particle types mainly in the liver and bladder already after 30 minutes following the injection (Figure 4A). The liver signal decreased gradually at later time points and was still above background levels at 48 h for both ~100 nm and ~200 nm particles. The presence of high fluorescence signal in the bladder at 0.5 h was an interesting observation, which could be related to the excretion of free dye molecules that were burst-released. In fact, intact particles cannot pass through the renal filtration barrier since it has an effective size cut-off of ~10 nm [81]. The higher percentage of burst release displayed by ~100 nm particles *in situ* aligned well with the *in vivo* observations, in which the bladder signal resulting from the excretion of the free dye molecules was relatively lower for ~200 nm particles. Overall, the bladder signal did not provide a reliable measure of the systemic clearance of the particles due to the interference of the burst-released dye. Thus, we monitored the clearance of particles from the liver as a representative of their systemic clearance.



**Figure 4.** A) Fluorescent whole body images of mice obtained at different time points up to 48 h after i.v. administration of ~200 nm and ~100 nm PLGA particles. Liver and bladder are encircled. B) Variations of liver fluorescence in whole body images. The fluorescence intensities are normalized at maximum values observed at 3 h after administration of ~100 nm (blue) and ~200 nm (green) PLGA particles. C) Variations of liver fluorescence intensities of ~100 nm (blue) and ~200 nm (green) PLGA particles obtained on isolated liver at 24 h and 48 h after particle administration. Data obtained for untreated mice (negative control) are shown in black.

The variation of liver signal was monitored using the whole-body images obtained at different time points (Figure 4B). For a better comparison, the values were normalized to maximum intensities measured at 3 h. From this point on, the decay of liver signal was almost linear for ~100 nm particles with a slope of -0.014 ( $R^2$  0.9926) (Figure 4B, blue curve), whereas the decay of ~200 nm particles better suited to an exponential function (Figure 4B, green curve). Since the number of fit points was not sufficient for an accurate exponential fit, we used a linear fit for ~200 nm particles as well. These particles displayed a relatively faster decay with a slope of -0.018 ( $R^2$  0.9537). *Ex-vivo* imaging of isolated liver also showed similar variations in signal intensities, such that ~200 nm particles (Figure 4C, green curve) displayed a more pronounced decrease at 48 h compared to ~100 nm particles (Figure 4C, blue curve). Faster clearance of larger particles was also shown in other studies. When

administered intravenously, particles larger than 200 nm activate human complement systems, are rapidly eliminated from the bloodstream and gathered mainly in the liver and spleen where the rate of accumulation is proportional to the size of the particles [30]. While particles with a diameter greater than 200 nm were most likely cleared by Kupffer cells, smaller particles displayed a decreased rate of clearance and an extended circulation time [82]. Of note, we did not observe a signal originating from the spleen in whole-body imaging. However, *ex-vivo* imaging of isolated spleen at 24 h and 48 h revealed signal intensities that were only slightly above the background noise, indicating that spleen was not the preferential accumulation site for sub-micron PLGA particles (Supp. Fig.2). Indeed, it has been reported that spleen receives barely 15 % of the i.v. injected dose of nanomedicines [83]. Therefore, additional surface modification strategies may be needed for applications that require splenic accumulation of PLGA particles.

## Conclusion

In this study, we demonstrated how PLGA particle size can be specifically tuned using a microfluidics system via modulating the formulation and process parameters. Through a series of optimization experiments, we obtained PEGylated PLGA particles in different sizes, which remarkably affected the characteristics of the particles *in vitro* and *in vivo* confirming the direct relation between the size and the pharmacokinetics behavior. This work can be considered as a further step towards the establishment of a production process that is able to generate tailor-made medicine for each individual clinical need.

## Acknowledgements

Authors acknowledge the financial support by EU grant PRECIOUS (686089). CF received the NWO Spinoza grant, ERC Advanced Grant Pathfinder (269019) and Dutch cancer society award 2009-4402.

## References

1. Khalid, M.; El-Sawy, H.S. Polymeric nanoparticles: Promising platform for drug delivery. *International journal of pharmaceutics* **2017**, *528*, 675-691.
2. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and surfaces B: biointerfaces* **2010**, *75*, 1-18.
3. ud Din, F.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. *International journal of nanomedicine* **2017**, *12*, 7291.
4. Chan, J.M.; Valencia, P.M.; Zhang, L.; Langer, R.; Farokhzad, O.C. Polymeric nanoparticles for drug delivery. In *Cancer Nanotechnology*, Springer: 2010; pp. 163-175.
5. Hines, D.J.; Kaplan, D.L. Poly (lactic-co-glycolic) acid- controlled-release systems: experimental and modeling insights. *Critical Reviews™ in Therapeutic Drug Carrier Systems* **2013**, *30*.
6. Danhier, F.; Ansorena, E.; Silva, J.M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-based nanoparticles: an overview of biomedical applications. *Journal of controlled release* **2012**, *161*, 505-522.
7. Makadia, H.K.; Siegel, S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers* **2011**, *3*, 1377-1397.
8. Operti, M.C.; Fecher, D.; van Dinther, E.A.; Grimm, S.; Jaber, R.; Figdor, C.G.; Tagit, O. A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles. *International journal of pharmaceutics* **2018**, *550*, 140-148.

9. Derakhshandeh, K.; Erfan, M.; Dadashzadeh, S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. *European journal of pharmaceutics and biopharmaceutics* **2007**, *66*, 34-41.
10. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. *Journal of controlled release* **2002**, *83*, 273-286.
11. Jose, S.; Juna, B.; Cinu, T.; Jyoti, H.; Aleykutty, N. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies. *Colloids and Surfaces B: Biointerfaces* **2016**, *142*, 307-314.
12. Khan, I.; Gothwal, A.; Sharma, A.K.; Kesharwani, P.; Gupta, L.; Iyer, A.K.; Gupta, U. PLGA nanoparticles and their versatile role in anticancer drug delivery. *Critical Reviews™ in Therapeutic Drug Carrier Systems* **2016**, *33*.
13. Sun, S.-B.; Liu, P.; Shao, F.-M.; Miao, Q.-L. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. *International journal of clinical and experimental medicine* **2015**, *8*, 19670.
14. Feczko, T.; Tóth, J.; Dósa, G.; Gyenis, J. Optimization of protein encapsulation in PLGA nanoparticles. *Chemical Engineering and Processing: Process Intensification* **2011**, *50*, 757-765.
15. Mohammadi-Samani, S.; Taghipour, B. PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches. *Pharmaceutical development and technology* **2015**, *20*, 385-393.
16. Pirooznia, N.; Hasannia, S.; Lotfi, A.S.; Ghanei, M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. *Journal of nanobiotechnology* **2012**, *10*, 20.
17. Rescignano, N.; Tarpani, L.; Tiribuzi, R.; Montesano, S.; Martino, S.; Latterini, L.; Kenny, J.M.; Armentano, I. Protein encapsulation in biodegradable polymeric nanoparticles: morphology, fluorescence behaviour and stem cell uptake. *Macromolecular bioscience* **2013**, *13*, 1204-1212.
18. Santander-Ortega, M.J.; Csaba, N.; González, L.; Bastos-González, D.; Ortega-Vinuesa, J.L.; Alonso, M.J. Protein-loaded PLGA–PEO blend nanoparticles: encapsulation, release and degradation characteristics. *Colloid and Polymer Science* **2010**, *288*, 141-150.
19. Lü, J.-M.; Liang, Z.; Wang, X.; Gu, J.; Yao, Q.; Chen, C. New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery. *Nanomedicine* **2016**, *11*, 1971-1991.
20. Patil, Y.B.; Swaminathan, S.K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. *Biomaterials* **2010**, *31*, 358-365.
21. Harguindey, A.; Domaille, D.W.; Fairbanks, B.D.; Wagner, J.; Bowman, C.N.; Cha, J.N. Synthesis and Assembly of Click-Nucleic-Acid-Containing PEG–PLGA Nanoparticles for DNA Delivery. *Advanced Materials* **2017**, *29*, 1700743.
22. Cun, D.; Jensen, D.K.; Maltesen, M.J.; Bunker, M.; Whiteside, P.; Scurr, D.; Foged, C.; Nielsen, H.M. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. *European Journal of Pharmaceutics and Biopharmaceutics* **2011**, *77*, 26-35.
23. Colombo, S.; Cun, D.; Remaut, K.; Bunker, M.; Zhang, J.; Martin-Bertelsen, B.; Yaghmur, A.; Braeckmans, K.; Nielsen, H.M.; Foged, C. Mechanistic profiling of the siRNA delivery dynamics of lipid–polymer hybrid nanoparticles. *Journal of controlled release* **2015**, *201*, 22-31.

24. Park, Y.-M.; Lee, S.J.; Kim, Y.S.; Lee, M.H.; Cha, G.S.; Jung, I.D.; Kang, T.H.; Han, H.D. Nanoparticle-based vaccine delivery for cancer immunotherapy. *Immune network* **2013**, *13*, 177-183.
25. Prasad, S.; Cody, V.; Saucier-Sawyer, J.K.; Saltzman, W.M.; Sasaki, C.T.; Edelson, R.L.; Birchall, M.A.; Hanlon, D.J. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. *Nanomedicine: Nanotechnology, Biology and Medicine* **2011**, *7*, 1-10.
26. Ma, T.; Wang, L.; Yang, T.; Ma, G.; Wang, S. Homogeneous PLGA-lipid nanoparticle as a promising oral vaccine delivery system for ovalbumin. *asian journal of pharmaceutical sciences* **2014**, *9*, 129-136.
27. Dölen, Y.; Kreutz, M.; Gileadi, U.; Tel, J.; Vasaturo, A.; van Dinther, E.A.; van Hout-Kuijper, M.A.; Cerundolo, V.; Figdor, C.G. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. *Oncoimmunology* **2016**, *5*, e1068493.
28. Clawson, C.; Huang, C.-T.; Futalan, D.; Seible, D.M.; Saenz, R.; Larsson, M.; Ma, W.; Minev, B.; Zhang, F.; Ozkan, M. Delivery of a peptide via poly (d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. *Nanomedicine: Nanotechnology, Biology and Medicine* **2010**, *6*, 651-661.
29. Allahyari, M.; Mohit, E. Peptide/protein vaccine delivery system based on PLGA particles. *Human Vaccines & Immunotherapeutics* **2016**, *12*, 806-828.
30. Hoshyar, N.; Gray, S.; Han, H.; Bao, G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. *Nanomedicine* **2016**, *11*, 673-692.
31. Han, F.Y.; Thurecht, K.J.; Whittaker, A.K.; Smith, M.T. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. *Frontiers in pharmacology* **2016**, *7*, 185.
32. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. *The American journal of pathology* **2000**, *156*, 1363-1380.
33. Toy, R.; Hayden, E.; Shoup, C.; Baskaran, H.; Karathanasis, E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. *Nanotechnology* **2011**, *22*, 115101.
34. Moghimi, S.M.; Parhamifar, L.; Ahmadvand, D.; Wibroe, P.P.; Andresen, T.; Farhangrazi, Z.; Hunter, A. Particulate systems for targeting of macrophages: basic and therapeutic concepts. *Journal of innate immunity* **2012**, *4*, 509-528.
35. Xie, Y.; Bagby, T.R.; Cohen, M.S.; Forrest, M.L. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. *Expert opinion on drug delivery* **2009**, *6*, 785-792.
36. Bazile, D.; Ropert, C.; Huve, P.; Verrecchia, T.; Mariard, M.; Frydman, A.; Veillard, M.; Spenlehauer, G. Body distribution of fully biodegradable [<sup>14</sup>C]-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. *Biomaterials* **1992**, *13*, 1093-1102.
37. Verhoef, J.J.; Anchordoquy, T.J. Questioning the use of PEGylation for drug delivery. *Drug delivery and translational research* **2013**, *3*, 499-503.
38. Suk, J.S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Advanced drug delivery reviews* **2016**, *99*, 28-51.

39. Schöttler, S.; Becker, G.; Winzen, S.; Steinbach, T.; Mohr, K.; Landfester, K.; Mailänder, V.; Wurm, F.R. Protein adsorption is required for stealth effect of poly (ethylene glycol)-and poly (phosphoester)-coated nanocarriers. *Nature nanotechnology* **2016**, *11*, 372.
40. Simon, J.; Müller, L.K.; Kokkinopoulou, M.; Lieberwirth, I.; Morsbach, S.; Landfester, K.; Mailänder, V. Exploiting the biomolecular corona: Pre-coating of nanoparticles enables controlled cellular interactions. *Nanoscale* **2018**, *10*, 10731-10739.
41. Morikawa, Y.; Tagami, T.; Hoshikawa, A.; Ozeki, T. The use of an efficient microfluidic mixing system for generating stabilized polymeric nanoparticles for controlled drug release. *Biological and Pharmaceutical Bulletin* **2018**, *41*, 899-907.
42. Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. *Pharmaceutics* **2018**, *10*, 57.
43. Bahari, L.A.S.; Hamishehkar, H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. *Advanced pharmaceutical bulletin* **2016**, *6*, 143.
44. Chiesa, E.; Dorati, R.; Pisani, S.; Conti, B.; Bergamini, G.; Modena, T.; Genta, I. The microfluidic technique and the manufacturing of polysaccharide nanoparticles. *Pharmaceutics* **2018**, *10*, 267.
45. Whitesides, G.M. The origins and the future of microfluidics. *Nature* **2006**, *442*, 368.
46. Mark, D.; Haeberle, S.; Roth, G.; Von Stetten, F.; Zengerle, R. Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. In *Microfluidics based microsystems*, Springer: 2010; pp. 305-376.
47. Amoyav, B.; Benny, O. Controlled and tunable polymer particles' production using a single microfluidic device. *Applied Nanoscience* **2018**, *8*, 905-914.
48. Dashtimoghadam, E.; Fahimipour, F.; Davaji, B.; Hasani-Sadrabadi, M.; Tayebi, L. Microfluidic-directed synthesis of polymeric nanoparticles for bone cancer therapy. *Dental Materials* **2016**, *1*, e59-e60.
49. de Solorzano, I.O.; Uson, L.; Larrea, A.; Miana, M.; Sebastian, V.; Arruebo, M. Continuous synthesis of drug-loaded nanoparticles using microchannel emulsification and numerical modeling: effect of passive mixing. *International journal of nanomedicine* **2016**, *11*, 3397.
50. Khan, I.U.; Serra, C.A.; Anton, N.; Vandamme, T.F. Production of nanoparticle drug delivery systems with microfluidics tools. *Expert opinion on drug delivery* **2015**, *12*, 547-562.
51. Xie, H.; Smith, J.W. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system. *Journal of nanobiotechnology* **2010**, *8*, 18.
52. Xu, J.; Zhang, S.; Machado, A.; Lecommandoux, S.; Sandre, O.; Gu, F.; Colin, A. Controllable microfluidic production of drug-loaded PLGA nanoparticles using partially water-miscible mixed solvent microdroplets as a precursor. *Scientific reports* **2017**, *7*, 4794.
53. Gdowski, A.; Johnson, K.; Shah, S.; Gryczynski, I.; Vishwanatha, J.; Ranjan, A. Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials. *Journal of nanobiotechnology* **2018**, *16*, 12.
54. Huang, W.; Zhang, C. Tuning the Size of Poly (lactic-co-glycolic Acid)(PLGA) Nanoparticles Fabricated by Nanoprecipitation. *Biotechnology journal* **2018**, *13*, 1700203.

55. Halayqa, M.; Domańska, U. PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release. *International journal of molecular sciences* **2014**, *15*, 23909-23923.
56. Tang, Q.; Si, W.; Huang, C.; Ding, K.; Huang, W.; Chen, P.; Zhang, Q.; Dong, X. An aza-BODIPY photosensitizer for photoacoustic and photothermal imaging guided dual modal cancer phototherapy. *Journal of Materials Chemistry B* **2017**, *5*, 1566-1573.
57. Trofymchuk, K.; Valanciunaite, J.; Andreiuk, B.; Reisch, A.; Collot, M.; Klymchenko, A.S. BODIPY-loaded polymer nanoparticles: chemical structure of cargo defines leakage from nanocarrier in living cells. *Journal of Materials Chemistry B* **2019**.
58. Devaraj, N.K.; Keliher, E.J.; Thurber, G.M.; Nahrendorf, M.; Weissleder, R. 18F labeled nanoparticles for in vivo PET-CT imaging. *Bioconjugate chemistry* **2009**, *20*, 397-401.
59. Elsbahy, M.; Heo, G.S.; Lim, S.-M.; Sun, G.; Wooley, K.L. Polymeric nanostructures for imaging and therapy. *Chemical reviews* **2015**, *115*, 10967-11011.
60. Mura, S.; Hillaireau, H.; Nicolas, J.; Le Droumaguet, B.; Gueutin, C.; Zanna, S.; Tsapis, N.; Fattal, E. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. *International journal of nanomedicine* **2011**, *6*, 2591.
61. de Jesus Gomes, A.; Lunardi, C.N.; Caetano, F.H.; Lunardi, L.O.; da Hora Machado, A.E. Phagocytosis of PLGA microparticles in rat peritoneal exudate cells: a time-dependent study. *Microscopy and Microanalysis* **2006**, *12*, 399-405.
62. Pisani, E.; Fattal, E.; Paris, J.; Ringard, C.; Rosilio, V.; Tsapis, N. Surfactant dependent morphology of polymeric capsules of perfluorooctyl bromide: influence of polymer adsorption at the dichloromethane–water interface. *Journal of colloid and interface science* **2008**, *326*, 66-71.
63. Honary, S.; Zahir, F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). *Tropical Journal of Pharmaceutical Research* **2013**, *12*, 255-264.
64. Jyothi, N.V.N.; Prasanna, P.M.; Sakarkar, S.N.; Prabha, K.S.; Ramaiah, P.S.; Srawan, G. Microencapsulation techniques, factors influencing encapsulation efficiency. *Journal of microencapsulation* **2010**, *27*, 187-197.
65. Fredenberg, S.; Wahlgren, M.; Reslow, M.; Axelsson, A. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems—a review. *International journal of pharmaceutics* **2011**, *415*, 34-52.
66. Siepmann, J.; Elkharraz, K.; Siepmann, F.; Klose, D. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. *Biomacromolecules* **2005**, *6*, 2312-2319.
67. Chen, W.; Palazzo, A.; Hennink, W.E.; Kok, R.J. Effect of particle size on drug loading and release kinetics of gefitinib-loaded PLGA microspheres. *Molecular pharmaceutics* **2016**, *14*, 459-467.
68. Dutta, D.; Salifu, M.; Sirianni, R.W.; Stabenfeldt, S.E. Tailoring sub-micron PLGA particle release profiles via centrifugal fractioning. *Journal of Biomedical Materials Research Part A* **2016**, *104*, 688-696.
69. Moayedian, T.; Mosaffa, F.; Khameneh, B.; Tafaghodi, M. Combined effects of PEGylation and particle size on uptake of PLGA particles by macrophage cells. *Nanomedicine Journal* **2015**, *2*, 299-304.
70. Swider, E.; Maharjan, S.; Houkes, K.; van Riessen, N.K.; Figdor, C.; Srinivas, M.; Tagit, O. Förster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo. *ACS Applied Bio Materials* **2019**, *2*, 1131-1140, doi:10.1021/acsabm.8b00754.

71. Foged, C.; Brodin, B.; Frokjaer, S.; Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. *International journal of pharmaceutics* **2005**, *298*, 315-322.
72. Tonigold, M.; Mailänder, V. Endocytosis and intracellular processing of nanoparticles in dendritic cells: routes to effective immunonanomedicines. *Future Medicine*: 2016.
73. Cruz, L.J.; Tacken, P.J.; Fokkink, R.; Joosten, B.; Stuart, M.C.; Albericio, F.; Torensma, R.; Figdor, C.G. Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. *Journal of Controlled Release* **2010**, *144*, 118-126.
74. Helft, J.; Böttcher, J.; Chakravarty, P.; Zelenay, S.; Huotari, J.; Schraml, B.U.; Goubau, D.; e Sousa, C.R. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c<sup>+</sup> MHCII<sup>+</sup> macrophages and dendritic cells. *Immunity* **2015**, *42*, 1197-1211.
75. Gonzalez-Junca, A.; Driscoll, K.; Pellicciotta, I.; Du, S.; Lo, C.H.; Roy, R.; Parry, R.; TenVooren, I.; Marquez, D.; Spitzer, M.H. Autocrine TGF $\beta$  is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment. **2018**.
76. Albanese, A.; Tang, P.S.; Chan, W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. *Annual review of biomedical engineering* **2012**, *14*, 1-16.
77. Liu, X.; Huang, N.; Li, H.; Jin, Q.; Ji, J. Surface and size effects on cell interaction of gold nanoparticles with both phagocytic and nonphagocytic cells. *Langmuir* **2013**, *29*, 9138-9148.
78. Dreaden, E.C.; Austin, L.A.; Mackey, M.A.; El-Sayed, M.A. Size matters: gold nanoparticles in targeted cancer drug delivery. *Ther Deliv* **2012**, *3*, 457-478.
79. Jeon, H.-J.; Jeong, Y.-I.; Jang, M.-K.; Park, Y.-H.; Nah, J.-W. Effect of solvent on the preparation of surfactant-free poly (DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics. *International journal of pharmaceutics* **2000**, *207*, 99-108.
80. Kreuter, J. Nanoparticle-based drug delivery systems. *Journal of Controlled Release* **1991**, *16*, 169-176.
81. Zuckerman, J.E.; Choi, C.H.J.; Han, H.; Davis, M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. *Proceedings of the National Academy of Sciences* **2012**, *109*, 3137-3142.
82. Kulkarni, S.A.; Feng, S.-S. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. *Pharmaceutical research* **2013**, *30*, 2512-2522.
83. Jindal, A.B. Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential. *Drug delivery and translational research* **2016**, *6*, 473-485.